Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening

Study Overview
=================
Brief Summary
-----------------
The goal of this pilot clinical trial is to determine feasibility and explore whether financial incentives paid to primary care patients for completing colorectal cancer screening increase completion of colorectal cancer screening. The main questions it aims to answer are: Do patient financial incentives for completing colorectal cancer screening increase screening completion? Does a patient financial incentive for colorectal cancer screening offered alongside patient financial incentives for COVID-19 and flu shots increase completion of those shots? Participants who are due for colorectal cancer screening will receive telephone outreach from primary care staff who will offer a stool-based colorectal cancer screening. Participants will be randomly assigned to either Group 1 or Group 2. Group 1 participants will be offered financial incentives for completing COVID-19 and flu shots within 2 months of enrollment. Group 2 participants will be offered financial incentives for completing a COVID-19 shot, a flu shot, and colorectal cancer screening within 2 months of enrollment. Researchers will compare to see if completion of a COVID-19 shot, a flu shot, and colorectal cancer screening is different between the two groups.

Official Title
-----------------
Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening

Conditions
-----------------
Health Behavior, Colorectal Cancer, Influenza, COVID-19, Vaccine Hesitancy, Vaccine-Preventable Diseases, Healthcare Patient Acceptance

Intervention / Treatment
-----------------
* Behavioral: Financial incentive for colorectal cancer screening
* Behavioral: Financial incentive for flu shot
* Behavioral: Financial incentive for COVID-19 shot


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 45 to 75 Receive care at participating primary care clinic Due for colorectal cancer screening Ability to understand and speak English Exclusion Criteria: Currently participating in another clinical trial or research study on colorectal cancer screening Unable or unwilling to give informed consent

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Interventional Model Description: Participants will be randomly assigned to a study arm for the duration of their two months in the study
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Full financial incentives<br>$50/service patient financial incentive for completion of: COVID-19 shot, flu shot, colorectal cancer screening | Behavioral: Financial incentive for colorectal cancer screening<br>* $50 incentive paid to participant for completion of colorectal cancer screening within 2 months of enrollment<br>Behavioral: Financial incentive for flu shot<br>* $50 incentive paid to participant for completion of flu shot within 2 months of enrollment<br>Behavioral: Financial incentive for COVID-19 shot<br>* $50 incentive paid to participant for completion of COVID-19 shot within 2 months of enrollment<br>|
| Active Comparator: Partial financial incentives<br>$50/service patient financial incentive for completion of: COVID-19 shot, flu shot | Behavioral: Financial incentive for flu shot<br>* $50 incentive paid to participant for completion of flu shot within 2 months of enrollment<br>Behavioral: Financial incentive for COVID-19 shot<br>* $50 incentive paid to participant for completion of COVID-19 shot within 2 months of enrollment<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in proportion of participants completing colorectal cancer screening between study arms | Completion of colonoscopy, sigmoidoscopy, CT colonography, or stool-based colorectal cancer screening test as documented in electronic health record within two months of study enrollment | Two months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Difference in proportion of participants completing COVID-19 shot between study arms | Completion of COVID-19 shot as documented in electronic health record within two months of study enrollment | Two months | 
| Difference in proportion of participants completing flu shot between study arms | Completion of flu shot as documented in electronic health record within two months of study enrollment | Two months | 
| Difference in proportion of participants completing at least one of the following services between study arms: colorectal cancer screening, COVID-19 shot, flu shot | Completion of colorectal cancer screening (colonoscopy, sigmoidoscopy, CT colonography, or stool-based colorectal cancer screening test), COVID-19 shot, *OR* flu shot as documented in electronic health record within two months of study enrollment | Two months | 
| Difference in proportion of participants completing all three services between study arms: colorectal cancer screening, COVID-19 shot, flu shot | Completion of colorectal cancer screening (colonoscopy, sigmoidoscopy, CT colonography, or stool-based colorectal cancer screening test), COVID-19 shot, *AND* flu shot as documented in electronic health record within two months of study enrollment | Two months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cancer screening, Preventive healthcare, Vaccine uptake, Patient financial incentives, Federally qualified health center, Health services